Testosterone Decline Impacts Female Libido Directly

Testosterone’s Decline and Its Direct Impact on Libido

For many women, the experience of menopause includes a significant drop in sexual desire, a condition known as hypoactive sexual desire disorder (HSDD). While estrogen loss gets much of the attention, researchers point to testosterone as a central player in this change. Testosterone is the most abundant biologically active sex androgen in women, produced by the ovaries and adrenal glands. It works by binding to androgen receptors located throughout the body, including the brain, skin, and reproductive tissues.

As the 2026 review by Montero Bernaldez and colleagues from Florida International University explains, testosterone levels decline gradually with age and fall sharply after menopause or surgical removal of the ovaries. This drop can directly disrupt the neurobiological pathways responsible for sexual motivation and response. The brain’s hypothalamus and limbic system, which govern libido, are rich in androgen receptors. Without sufficient testosterone to activate these receptors, the drive for sexual activity often diminishes, leading to the distress and relationship strain characteristic of HSDD.

Symptom Diagnosis Trumps Blood Test Numbers

A major obstacle in addressing testosterone deficiency is diagnosis. The clinical review highlights that relying on a single serum testosterone level is often misleading. Hormone levels fluctuate daily and available lab assays are inconsistent. Instead, experts advocate a symptom-based clinical approach. A diagnosis of androgen insufficiency is made primarily on the presence of symptoms like persistent low libido, unexplained fatigue, and a general loss of well-being in a woman who has adequate estrogen levels. This method prioritizes the patient’s experience over a potentially unreliable number, ensuring treatment focuses on improving quality of life.

Testosterone Therapy is Effective, But Access is Limited

Decades of clinical use and research support the effectiveness of testosterone therapy for improving sexual desire, arousal, and satisfaction in menopausal women. The evidence points to subcutaneous implants and transdermal patches or gels as the most effective and stable delivery methods. A 2026 study led by Adrian Heald confirmed that transdermal testosterone gel, used alongside estrogen-based HRT, successfully raised serum testosterone levels in post-menopausal women with HSDD as part of routine care.

Despite nearly a century of global use and clear patient demand, no testosterone formulation is FDA-approved for women. This regulatory gap forces many to seek compounded therapies, which lack standardization and oversight. “Women deserve access to regulated, effective treatments grounded in scientific evidence,” the review authors conclude. This lack of approved products creates a significant barrier to safe, consistent care.

Safety Profile Appears Favorable at Therapeutic Doses

Concerns about side effects like acne, hirsutism (increased hair growth), and potential long-term risks often deter patients and clinicians. According to the aggregated evidence, side effects from testosterone therapy at doses intended to restore physiological levels are typically mild and reversible. The most common are acne and mild hirsutism, which often subside with dose adjustment.

Importantly, the authors note that existing long-term data, including from transgender medicine, have not shown increased risks of breast cancer or cardiovascular disease at these therapeutic doses. However, they explicitly state that high-quality, long-term randomized controlled trials are still urgently needed to establish definitive safety parameters. The absence of these trials contributes to ongoing caution and the FDA’s hesitancy.

Navigating Treatment Options in the Current Landscape

For women experiencing testosterone-deficient symptoms, a practical path forward involves several steps. First, a detailed consultation with a menopause-informed healthcare provider is essential to establish a symptom-based diagnosis. If testosterone therapy is considered, the goal is to use the lowest effective dose to relieve symptoms, monitored through clinical response rather than targeting a specific blood level.

Given the lack of FDA-approved products, providers may prescribe compounded creams or gels, but patients should be aware of the variability in these preparations. Off-label use of FDA-approved male products at meticulously adjusted, much lower doses is another common, though not ideal, pathway. For non-hormonal approaches to related symptoms like vaginal dryness, options include non-hormonal treatments for genitourinary syndrome of menopause. The evolving clinical guidance, including perspectives from other regions, is also summarized in resources like the Testosterone for Menopause: Latin American Position Statement.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42110023/
https://pubmed.ncbi.nlm.nih.gov/41834026/
https://pubmed.ncbi.nlm.nih.gov/38913119/